Wall Street equity research analysts tracking Ovid Therapeutics issue consensus 12-month price targets based on upcoming clinical trial readouts and pipeline catalysts. Consensus figures fluctuate dynamically; for example, average predictions gravitate around the $4.80 to $5.14 range, though forecasts vary widely depending on individual institutional methodologies.
Ovid Therapeutics Inc. maintains its primary corporate headquarters in New York City, New York, positioning its core management and research operations within a major U.S. life sciences and financial hub.
Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical firm specializing in programmed cellular immunotherapies.
When evaluating ticker symbols on stock exchanges, OVID refers to Ovid Therapeutics, a legitimate, SEC-reporting biopharmaceutical company.
Financial analysts issue rolling forecasts for Ovid Therapeutics driven by upcoming data readouts from its rare neurological drug pipeline.
Ovid Therapeutics trades on the NASDAQ Global Market under the ticker OVID.
Ovid Therapeutics Inc. (NASDAQ: OVID) is a biopharmaceutical enterprise focused on developing novel medicines for rare neurological and rare brain disorders.
Ovid Therapeutics (NASDAQ: OVID) operates in the specialized biopharmaceutical sector focusing on rare neurological diseases.
Yes, you can still sell a delisted stock, though liquidity is severely restricted. When an equity is removed from major exchanges like the NASDAQ or NYSE, it typically moves to Over-the-Counter (OTC) pink sheets or bulletin boards.
Delisting alone does not automatically erase the value of your shares or mean you lose all your money. It simply means the stock no longer trades on a major national exchange.
Wall Street equity research analysts tracking Ovid Therapeutics maintain a consensus 12-month average price target hovering around $5.
Ovid Therapeutics (NASDAQ: OVID) trades around $2.80 per share, with a market capitalization of approximately $546 million.
Ovid Therapeutics is a clinical-stage biopharmaceutical enterprise dedicated to developing targeted small-molecule medicines and precision treatments for rare neurological conditions, seizure disorders, and brain diseases with significant unmet medic...
The Chief Executive Officer of Ovid Therapeutics is Meg Alexander, who assumed the role after serving as President and Chief Operating Officer, succeeding co-founder Dr. Jeremy M.
Ovid Therapeutics officially became a publicly traded company in May 2017, pricing its initial public offering (IPO) on the NASDAQ Global Market under the ticker symbol OVID to raise capital for advancing its neuroscience clinical development program...
Ovid Therapeutics has a dividend yield of 0.00%.
No, Ovid Therapeutics does not pay dividends.
The future prospects of Ovid Therapeutics hinge heavily on the clinical progression and commercialization potential of its proprietary pipeline, which features next-generation GABA-aminotransferase inhibitors like OV329 and KCC2 direct activators tar...
Deciding whether to liquidate your position in Ovid Therapeutics depends heavily on your individual risk tolerance, portfolio diversification rules, and timeline for clinical trial milestones.
Ovid Therapeutics holds significant importance in the biotechnology landscape due to its dedicated focus on developing targeted medicines for rare neurological conditions and orphan diseases—such as Angelman syndrome, Dravet syndrome, and fragile X s...
Whether Ovid Therapeutics (NASDAQ: OVID) represents a sound purchase depends strictly on your individual risk tolerance, investment horizon, and strategy for speculative clinical-stage biotech equities.
Equity analysts covering Viking Therapeutics (NASDAQ: VKTX) maintain a consensus "Strong Buy" rating with a 12-month average price target hovering around $92 to $99, featuring forecasts stretching up to a high estimate of $125.
Ovid Therapeutics operates as a lean, specialized biopharmaceutical organization with a compact workforce typically numbering between 23 and 25 full-time employees.